

Manufacturer Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volume	WAC (as of date of commercial availability)	Date of Commercial Availability	Estimated volume of patients who may be prescribed drug	Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A	A description of the marketing and pricing plans used in the launch of the new drug
Quallent Pharmaceuticals	82009014422	ADALIMUMAB-ADB 40MG/0.4ML PEN 2-PACK Kit	40mg/0.4ml	2	\$3,750.00	5/28/2024	Information Not Publicly Available	N	N	N/A	Information Not Publicly Available
Quallent Pharmaceuticals	82009014622	ADALIMUMAB-ADB 40MG/0.4ML PFS 2-PACK KIT	40mg/0.4ml	2	\$3,750.00	5/28/2024	Information Not Publicly Available	N	N	N/A	Information Not Publicly Available
Quallent Pharmaceuticals	82009015622	ADALIMUMAB-RYVK 40MG/0.4ML PEN 2-PACK KIT	40mg/0.4ml	2	\$3,750.00	5/28/2024	Information Not Publicly Available	N	N	N/A	Information Not Publicly Available
Quallent Pharmaceuticals	82009014822	Adalimumab-adbm 40 MG / 0.8 ML Pen 2-Pack Kit	40mg/0.8ml	2	\$3,750.00	6/13/2024	Information Not Publicly Available	N	N	N/A	Information Not Publicly Available
Quallent Pharmaceuticals	82009015022	Adalimumab-adbm 40 MG / 0.8 ML PFS 2-Pack Kit	40mg/0.8ml	2	\$3,750.00	6/13/2024	Information Not Publicly Available	N	N	N/A	Information Not Publicly Available